ORIGINAL ARTICLE:

- Multi-centre post-implementation evaluation of SARS-CoV-2 antigen-based point of care tests used for asymptomatic screening of continuing care healthcare workers
- Jamil N Kanji^{a-d,*}, Dustin T Proctor^{d,e}, William Stokes^{b,c,f}, Byron M Berenger^{b,d}, James Silvius^g, Graham Tipples^{b,h.i}, A Mark Joffe^{f,j}, Allison A Venner^{d,e}

Affiliations:

1

2

3

4

8 9 10

11

12 13

14

18

24

272829

30

31 32

33

34 35

36

37

38

39 40

41

- Division of Infectious Diseases, Department of Medicine, University of Calgary School of Medicine, 3030 Hospital Drive NW, Calgary, AB, Canada, T2N 4W4
 - b. Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
- c. Department of Laboratory Medicine and Pathology, Faculty of Medicine and
 Dentistry, University of Alberta, 8440 112 Street NW, Edmonton, AB, Canada,
 T6G 2B7
- d. Department of Pathology and Laboratory Medicine, University of Calgary School of
 Medicine, 3535 Research Road NW, Calgary, AB, Canada, T2L 2K8
- e. Clinical Biochemistry, Alberta Precision Laboratories, Diagnostic and Scientific
 Center, 3535 Research Road NW, Calgary, AB, T2L 2K8
- f. Division of Infectious Diseases, Department of Medicine, University of Alberta, 8440
 112 Street NW, Edmonton, AB, Canada, T6G 2B7
 - g. Division of Geriatric Medicine, Cumming School of Medicine, 3030 Hospital Drive NW, Calgary, AB, Canada, T2N 4W4
 - h. Li Ka Shing Institute of Virology, 6-010 Katz Group Center for Pharmacy and Health Research, University of Alberta, Edmonton, AB, Canada, T6G 2E1
 - Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, 8440 – 112 Street NW, Edmonton, AB, Canada, T6G 2B7
 - j. Alberta Health Services, Seventh Street Plaza, 14th floor-North Tower, 10030 107 Street NW, Edmonton, AB, Canada, T5J 3E4
- 42 *Corresponding author:
- 43 Jamil N. Kanji, MD, DTM&H, FRCPC
- 44 Public Health Laboratory, Alberta Precision Laboratories
- 45 3030 Hospital Drive NW, Calgary, AB, Canada T2N 4W4
- 46 Phone: +1 403 944 1207; Fax: +1 403 283 0142
- 47 Email: jamil.kanji@albertahealthservices.ca
- 49 Word count (main manuscript): 2082

51 Abstract word count: 209

50

53 Abstract

54

- 55 OBJECTIVES
- 56 Frequent screening of SARS-CoV-2 among asymptomatic populations using antigen-based
- 57 point of care tests (APOCT) is occurring globally with limited clinical performance data.
- The positive predictive value (PPV) of two APOCT used in the asymptomatic screening of
- 59 SARS-CoV-2 among healthcare workers (HCW) at continuing care (CC) sites across Alberta,
- 60 Canada was evaluated.
- 61 METHODS
- 62 Between February 22 and May 2, 2021, CC sites implemented SARS-CoV-2 voluntary
- 63 screening of their asymptomatic HCW. Onsite testing with Abbott Panbio or BD Veritor
- occurred on a weekly or twice weekly basis. Positive APOCT were confirmed with a real-
- time reverse-transcriptase polymerase chain reaction (rRT-PCR) reference method.
- 66 RESULTS
- A total of 71,847 APOCT (17,689 Veritor and 54,158 Panbio) were performed among 369
- 68 CC sites. Eighty-seven (0.12%) APOCT were positive, of which 39 (0.05%) confirmed as
- true positives using rRT-PCR. Use of the Veritor and Panbio resulted in a 76.6% and 30.0%
- false positive detection, respectively (p<0.001). This corresponded to a 23.4% and 70.0%
- 71 PPV for the Veritor and Panbio, respectively.
- 72 CONCLUSIONS

- 73 Frequent screening of SARS-CoV-2 among asymptomatic HCW in CC, using APOCT,
- 74 resulted in a very low detection rate and a high detection of false positives. Careful
- 75 assessment between the risks vs benefits of APOCT programs in this population needs to be
- 76 thoroughly considered before implementation.
- 78 Key words: point-of-care, SARS-CoV-2 antigen, positive predictive value, sensitivity

80 81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

Introduction

Point of Care Testing (POCT), and specifically antigen-based point of care tests (APOCT), represent an important public health measure in managing SARS-CoV-2 transmissions when used appropriately and with acknowledgement of their shortcomings. APOCT is particularly useful in identifying and isolating SARS-CoV-2 positive cases in symptomatic individuals in high-risk settings, such as congregate housing and care facilities or in areas where longer turn-around-times (TAT) of more sensitive nucleic acid testing may compromise containment of transmission. Governments around the world have been quick to support the widescale implementation of APOCT programs [1]. Rapid and wide-scale deployment of APOCT has been promoted despite limited data regarding the analytical and clinical performance of these devices in the various settings in which they have been used. POCT programs that include APOCT have been criticised for the poor sensitivity of these tests compared to PCR tests, particularly in asymptomatic individuals [2]. However, there has been intense interest in testing asymptomatic individuals from a public health perspective, as some estimate that 30 to 40 percent of infectious individuals are asymptomatic. Rapid identification and isolation of these individuals is viewed as highly effective in breaking chains of transmission [1, 3-5]. However, there is concern that APOCT may demonstrate poor specificity when used for the surveillance of asymptomatic individuals, with reports citing up to 60% false positive rates [6, 7]. Routine serial testing of asymptomatic staff in continuing care facilities using APOCT has been implemented as a purportedly important public health measure for early case identification, and prevention of SARS-CoV-2 outbreaks among vulnerable residents [1, 3-5].

106

107

108

109

110

111

112

113

114

115116

117

118

119

120

121

122

123

124

125

126

127

128

129

While APOCT may represent an important tool in limiting transmission in congregate settings, the negative impacts of a false positive result for staff and the site needs to be considered and further data on the clinical performance of APOCT in continuing care facilities is required. Our aim was to evaluate the positive predictive value (PPV) of two APOCT (Abbott PanbioTM and BD VeritorTM) in a largescale multicenter implementation of asymptomatic SARS-CoV-2 testing of healthcare workers (HCWs) in continuing care facilities. Methods Setting Asymptomatic SARS-CoV-2 testing of HCWs in continuing care facilities province-wide was implemented as POCT as part of the provincial pandemic response in the province of Alberta, Canada (population 4.4 million) [8]. A retrospective review of test results was completed for testing completed from February 22, 2021 – May 2, 2021 inclusive. Facilities were assigned (based on availability, oversight, and preference) to use either the Panbio COVID-19 Antigen Rapid Test (Abbott Laboratories, Chicago, USA) or the Veritor COVID-19 Rapid Antigen Test (Becton, Dickson, and Company, Franklin Lakes, USA), herein referred to as APOCT. Early in the pandemic, the provincial health authority had instituted a continuous masking policy for all continuing care facilities, where all staff were required to continuously wear a medical mask while at work, to be changed should the mask become soiled or wet [9]. Adjunctive eye protection (face shield or goggles) was advised during all episodes of patient

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

care, or continuously if there was a SARS-CoV-2 outbreak declared at the site [10]. HCWs at all facilities were required to complete a 'fit for work' symptom questionnaire twice per shift, and immediately leave their shift after informing their manager and arrange COVID-19 testing should they develop symptoms or screen positive [11]. Asymptomatic testing Each site received training for a limited number of on-site health care workers to conduct voluntary asymptomatic staff testing of site staff on a weekly basis. Training, operating procedures and medical/operational oversight were provided by Alberta Precision Laboratories (APL) POCT (for sites run by Alberta Health Services [AHS]). Sites external to AHS had vendor-driven training and medical/operational oversight was provided by the site. Staff conducting testing wore personal protective equipment (PPE) consisting of eye protection, surgical mask, gloves, and a splash-resistant gown. Sampling was done using the nasal swab provided in each test kit with testing conducted as per manufacturer's guidelines [12, 13]. While awaiting results, staff were permitted to continue working. Staff who were symptomatic were not permitted to receive POCT asymptomatic testing and were directed to access COVID-19 testing through public health test centers. At the discretion of individual facilities, staff testing could be increased to twice weekly for non-outbreak related staff at a site where a COVID-19 outbreak had been declared (staff considered linked to the outbreak were not eligible for asymptomatic testing). Staff receiving positive APOCT results were required to immediately isolate and obtain a confirmatory throat or nasopharyngeal swab test for SARS-CoV-2 with a real-time reversetranscriptase polymerase chain reaction (rRT-PCR) result at an approved public health test

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175176

177

center. rRT-PCR testing was carried out at the provincial Public Health Laboratory (ProvLab) using a validated laboratory-developed assay [14] or a Health Canada approved test at an accredited laboratory. Confirmatory rRT-PCR testing was not conducted on negative SARS-CoV-2 APOCT results. Individuals with invalid APOCT results were referred for rRT-PCR evaluation. APOCT test results were not recorded in the medical chart of HCWs. Any positive APOCT results were considered presumptive positive and were not included in total provincial COVID-19 case counts, using instead the confirmatory rRT-PCR results. All HCWs with a positive APOCT result were able to obtain a follow-up rRT-PCR test. Data extraction and analysis Data recording, organization, and provision of results were provided by Seniors Health and Continuing Care (AHS). Confirmatory rRT-PCR testing results were extracted from the ProvLab laboratory information system. Data were tabulated in Microsoft Excel. Proportional comparisons were done using a two-sample proportions z-test. Continuous variables were compared using Mann-Whitney tests while categorical variables were compared using Chi-square or Fisher's exact tests. Significance was set at p<0.05. Confidence intervals were calculated using Wilson's method. Statistical analysis was conducted using StatPlus (AnalystSoft Inc, Alexandria, USA). Results Over the 10-week period, 369/466 (79.18%) provincial continuing care sites participated in the asymptomatic screening program (Table 1). During the study period, 71,847 APOCT

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

were conducted (mean 7,184.7 tests per week; range 615-11648; 17,689 on the Veritor and 54,158 on the Abbott Panbio) (Table 2). A total of 87 (0.12%) APOCT were positive, of which 39 (44.83%) were confirmed to be true positives using rRT-PCR (time duration between APOCT and rRT-PCR confirmation not available). The APOCT positivity rate did not differ significantly across the ten-week period (Table 1; p=0.35). Compared to the Panbio, the false detection rate was significantly higher using the Veritor (76.6%, 95% confidence interval (CI) 62.8-86.4% vs 30.0%, 95% CI 18.1-45.4%; p<0.0001) (Table 2). The PPV was significantly higher with the Panbio test (70%, 95%CI 54.6-81.9% vs 23.4%, 95%CI 13.6-37.2%; p<0.0001). During this time, a total of 66,338 cases of COVID-19 were diagnosed in Alberta (prevalence of 1.5%) with an average rRT-PCR positivity rate (for all specimens tested) of 7.2% (median 6.3%; range 3.8-13.6%) [15]. During the study period, a total of 32 outbreaks were declared in continuing care facilities across the province (one in March 2021, 29 in April 2021, and two in May 2021). HCWs in continuing care facilities were offered mRNA COVID-19 vaccines starting December 16, 2020 alongside the residents in these facilities (dosing between first doses being four and six weeks for residents and HCWs respectively). The proportion of all HCWs working in Alberta continuing care facilities who had received one dose of COVID-19 vaccine as of February 1 and May 2, 2021 was 1.1 and 69.9% respectively. The proportion having received two doses of vaccine by these dates was 16.0 and 83.6% respectively. The demographics and proportions of vaccinated HCWs tested were not available, as neither were the follow-up rRT-PCR testing results of 87 individuals with invalid APOCT results.

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

Discussion Despite great emphasis on the use of APOCT as a tool to combat the COVID-19 pandemic, expansion of APOCT for asymptomatic testing has been met with hesitation due to their limited PPV, especially in settings of low disease prevalence [16]. This study confirms and quantitates these concerns, demonstrating in a large-scale implementation of asymptomatic screening in continuing care HCWs, that APOCT have a low overall PPV (44.83%) and a high proportion of false positives (55.17%). Similar performance concerns related to APOCT have been raised by a number of studies. A recent Cochrane Database systematic review reported the overall sensitivity (Sn) and specificity (Sp) of APOCT in symptomatic disease to be 72.0 and 99.5% (twenty-seven studies combined) and asymptomatic disease to be 58.1% and 98.9% respectively (twelve studies combined) [2]. Applying this to the provincial prevalence of disease we observed during the study period (1.5%), indicates our findings are consistent, with an expected PPV for APOCT around 44.6%. Several studies have reported a PPV as low as 33.3% [17, 18]. Many reports of asymptomatic SARS-CoV-2 testing campaigns using either APOCT or rRT-PCR tests have demonstrated low test positivity rates, suggesting high volume testing of asymptomatic individuals is of low yield [19-22]. Another Canadian study evaluating universal APOCT screening of HCWs in continuing care also found a similar APOCT positivity rate of 0.16% [23]. The prevalence of positive results in our cohort was similar at 0.12%, however the true prevalence of disease in our cohort is much less if true positives are accounted for (0.05%). Therefore, when considering the true positivity rate, the yield of asymptomatic screening programs is poor.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

The Veritor displayed both a lower PPV and a higher proportion of false positive tests compared to the Panbio. Both tests were initially authorised by the FDA and Health Canada for the diagnosis of COVID-19 within the first five (Veritor) to seven (Panbio) days of COVID-19 symptom onset [16]. Our findings are consistent with the literature, demonstrating the PPVs for the Veritor in asymptomatic individuals ranging from 24.9-50.1% (with disease prevalence of 0.5-1.5%) [24] and that of the Panbio to be 28.0-54.0%, using prevalence estimates of 0.5-1.5% [24-26]. Thus, the Panbio would be preferred over the Veritor for asymptomatic screening of COVID-19. The impact of a false positive result can lead to considerable burden and distress on both individuals and the health care system. False positive test results in HCWs and others can lead to loss of income due to the need to isolate, collateral effects to close contacts, and also psychological damage due to misdiagnosis, stigma and fear of infecting others (especially loved ones who could have poor outcomes) [27]. In health care settings, the need for isolation in response to a false positive result can lead to staff shortages, adding further stress on other employees and patients. False positive APOCT results in acute care settings have resulted in unnecessary cancellation or postponement of treatment/procedures, and also risks that individual possibly being exposed to SARS-CoV-2 if moved into a COVID-19 treatment unit based on the APOCT result [28]. Thus, we strongly recommend proper education about the meaning of APOCT results, and ensuring processes are in place for timely confirmation with rRT-PCR if APOCT is implemented.

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

The setup of asymptomatic testing programs using APOCT requires considerable input of resources and logistical organization. To ensure the utmost quality of testing, APOCT should undergo appropriate test verification, creation of standard operating procedures and training programmes, and include appropriate medical and operational oversight through an accredited laboratory when implementing the associated POCT program [29]. Information technology specialists are generally required to establish reporting systems so that results can be accurately captured to facilitate public health reporting, disease notification, and contact tracing. Furthermore, ongoing oversight to address reporting errors, test distribution, and ongoing test validation must be built into the APOCT infrastructure [30]. The impact of false positive results, alongside these important operational considerations must be accounted for when deciding on the benefit of an APOCT screening program. The principal limitation of this study is that only positive APOCT tests were confirmed by rRT-PCR, and thus no other test parameters other than a PPV could be calculated. The data however, still confirms in a large asymptomatic HCW population, that APOCT has a low PPV. The major strengths of this study lie in the large number of tests performed, participating sites, and inclusion of two different APOCT platforms. The utility of screening asymptomatic individuals with COVID-19 APOCT is best determined by weighing the costs and benefits specific to each setting. With widespread vaccination increasing and disease prevalence falling, fewer positive test results are likely to be found among asymptomatic persons in the coming months (with a large proportion of them being false-positives), leading such endeavors to be quite costly from a materials and human resources perspectives for most health care systems. Therefore, it is important to

- 274 reconsider the value and effectiveness of asymptomatic APOCT COVID-19 programs over
- the long term, especially in the context of increasing population immunity.

277 **Declarations** 278 279 Ethics approval 280 Presentation of the data contained in this report has been approved by the Human Research 281 Ethics Board at the University of Alberta (study identifier Pro00110831). 282 283 Conflicts of interest 284 None of the authors have any conflicts of interests with respect to this manuscript to declare. 285 286 Funding 287 This work did not receive any specific grant from funding agencies in the public, commercial, 288 or not-for-profit sectors. Tests were purchased by the government of Canada and distributed 289 to provinces to aid in the COVID-19 response. All other resources used internal funds. 290 291 Acknowledgements 292 We would like to thank the Alberta Precision Laboratories POCT staff for their support to the 293 Panbio POCT program who developed and supported designated continuing care facilities. 294 We would also like to thank the staff within the Provincial Seniors Health program who 295 developed the program parameters and operationalised the program (Sandra Gugins and 296 Sharon Leontowicz), and participating Continuing Care sites, staff responsible for the 297 asymptomatic testing programs and those staff who participated in screening. 298 299 CRediT Author Statement 300 Jamil N Kanji – formal analysis, data curation, writing – original draft, writing – review and 301 editing, visualization

302 Dustin Proctor – validation, writing – original draft, writing – review and editing 303 William Stokes – conceptualization, methodology, validation, investigation, resources, 304 project administration, writing – original draft, writing – review and editing 305 Byron Berenger – conceptualization, validation, resources, writing – original draft, writing – 306 review and editing 307 James Silvius - conceptualization, validation, resources, project administration, writing – 308 review and editing 309 Graham Tipples - conceptualization, validation, resources, project administration, writing – 310 review and editing 311 Mark A Joffe - conceptualization, validation, resources, project administration, writing – 312 review and editing 313 Allison Venner – conceptualization, methodology, validation, investigation, resources, 314 project administration, writing – original draft, writing – review and editing, supervision 315 316 Availability of data and materials 317 The datasets used and/or analysed during the current study are available from the 318 corresponding author on reasonable request. 319 320 321

References

322

- 324 [1] Government of Canada, Priority strategies to optimize testing and screening for COVID-
- 325 19 in Canada: Report. < https://www.canada.ca/en/health-canada/services/drugs-health-
- 326 products/covid19-industry/medical-devices/testing-screening-advisory-panel/reports-
- 327 summaries/priority-strategies.html>, (accessed May 17, 2021.).
- 328 [2] J. Dinnes, J.J. Deeks, S. Berhane, M. Taylor, A. Adriano, C. Davenport, S. Dittrich, D.
- 329 Emperador, Y. Takwoingi, J. Cunningham, S. Beese, J. Domen, J. Dretzke, L. Ferrante di
- Ruffano, I.M. Harris, M.J. Price, S. Taylor-Phillips, L. Hooft, M.M. Leeflang, M.D. McInnes,
- R. Spijker, A. Van den Bruel, C.-D.T.A.G. Cochrane, Rapid, point-of-care antigen and
- 332 molecular-based tests for diagnosis of SARS-CoV-2 infection, Cochrane Database Syst Rev
- 333 3(3) (2021) CD013705-CD013705.
- 334 [3] A. Crozier, S. Rajan, I. Buchan, M. McKee, Put to the test: use of rapid testing
- 335 technologies for covid-19, BMJ 372 (2021) n208.
- 336 [4] M. Liu, R.K. Arora, M. Krajden, Rapid antigen tests for SARS-CoV-2, Canadian Medical
- 337 Association Journal 193(13) (2021) E447-E447.
- [5] Centers for Disease Control and Prevention (CDC), COVID-19 Pandemic Planning
- 339 Scenarios. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html,
- 340 (accessed May 17, 2021.).
- 341 [6] K. Wu, Nevada Halts Use of Rapid Coronavirus Tests in Nursing Homes, Citing
- 342 Inaccuracies, New York Times.
- 343 [7] S. Armstrong, Covid-19: Tests on students are highly inaccurate, early findings show,
- 344 BMJ 371 (2020) m4941.
- 345 [8] Government of Alberta, Population statistics. < https://www.alberta.ca/population-
- 346 <u>statistics.aspx</u>>, (accessed May 10, 2021.).

- [9] Alberta Health Services, Directive: Use of masks during COVID-19.
- 348 https://extranet.ahsnet.ca/teams/policydocuments/1/clp-ahs-use-of-masks-hcs-267.pdf,
- 349 (accessed May 10, 2021.).
- 350 [10] Alberta Health Services, Continuing Care Personal Protective Equipment (PPE) -
- Frequently Asked Questions. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-
- 352 covid-19-ppe-faq-continuing-care.pdf>, (accessed May 10, 2021.).
- 353 [11] Alberta Health Services, Fit For Work: COVID-19.
- 354 < https://www.albertahealthservices.ca/topics/Page17076.aspx>, (accessed May 15, 2021.).
- 355 [12] Abbott, Panbio COVID-19 Ag Rapid Test Device (Nasal). < https://dam.abbott.com/en-
- 356 gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-AsymptomaticSe.pdf>, (accessed
- 357 May 17, 2021.).
- 358 [13] D.a.C. Beckton, Veritor System for Rapid Detection of SARS-CoV-2.
- 359 < https://bdveritor.bd.com/content/dam/bdveritor/pdfs/BD-Veritor-IFU.pdf, (accessed May
- 360 17, 2021.).
- 361 [14] K. Pabbaraju, A.A. Wong, M. Douesnard, R. Ma, K. Gill, P. Dieu, K. Fonseca, N.
- 362 Zelyas, G.A. Tipples, Development and validation of RT-PCR assays for testing for SARS-
- 363 CoV-2, Official Journal of the Association of Medical Microbiology and Infectious Disease
- 364 Canada 6(1) (2021) 16-22.
- 365 [15] Government of Alberta, Cases in Alberta. https://www.alberta.ca/covid-19-alberta-
- 366 <u>data.aspx</u>>, May 17, 2021).
- 367 [16] R.W. Peeling, P.L. Olliaro, D.I. Boeras, N. Fongwen, Scaling up COVID-19 rapid
- antigen tests: promises and challenges, The Lancet Infectious Diseases.
- 369 [17] I.W. Pray, L. Ford, D. Cole, C. Lee, J.P. Bigouette, G.R. Abedi, D. Bushman, M.J.
- Delahoy, D. Currie, B. Cherney, M. Kirby, G. Fajardo, M. Caudill, K. Langolf, J. Kahrs, P.
- Kelly, C. Pitts, A. Lim, N. Aulik, A. Tamin, J.L. Harcourt, K. Queen, J. Zhang, B. Whitaker,

- H. Browne, M. Medrzycki, P. Shewmaker, J. Folster, B. Bankamp, M.D. Bowen, N.J.
- 373 Thornburg, K. Goffard, B. Limbago, A. Bateman, J.E. Tate, D. Gieryn, H.L. Kirking, R.
- Westergaard, M. Killerby, Performance of an Antigen-Based Test for Asymptomatic and
- 375 Symptomatic SARS-CoV-2 Testing at Two University Campuses Wisconsin, September-
- 376 October 2020, MMWR Morb Mortal Wkly Rep 69(5152) (2021) 1642-1647.
- 377 [18] M. Masiá, M. Fernández-González, M. Sánchez, M. Carvajal, J.A. García, N. Gonzalo-
- Jiménez, V. Ortiz de la Tabla, V. Agulló, I. Candela, J. Guijarro, J.A. Gutiérrez, C. de
- 379 Gregorio, F. Gutiérrez, Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-
- 380 Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk
- for Transmission and Older Age, Open Forum Infectious Diseases 8(3) (2021).
- 382 [19] P. Ravani, L. Saxinger, U. Chandran, K. Fonseca, S. Murphy, E. Lang, L. McDougall, B.
- 383 Manns, COVID-19 screening of asymptomatic patients admitted through emergency
- departments in Alberta: a prospective quality-improvement study, CMAJ Open 8(4) (2020)
- 385 E887-e894.
- 386 [20] J. Ferguson, S. Dunn, A. Best, J. Mirza, B. Percival, M. Mayhew, O. Megram, F.
- Ashford, T. White, E. Moles-Garcia, L. Crawford, T. Plant, A. Bosworth, M. Kidd, A.
- Richter, J. Deeks, A. McNally, Validation testing to determine the sensitivity of lateral flow
- testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing
- frequency and public health messaging is key, PLoS Biol 19(4) (2021) e3001216.
- 391 [21] J. Olalla, A.M. Correa, Martín-Escalante, M D, M.L. Hortas, M.J. Martín-Sendarrubias,
- V. Fuentes, Sena, G, J. García-Alegría, t.R. Group, Search for asymptomatic carriers of
- 393 SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience, QJM: An
- 394 International Journal of Medicine 113(11) (2020) 794-798.
- 395 [22] S. Cao, Y. Gan, C. Wang, M. Bachmann, S. Wei, J. Gong, Y. Huang, T. Wang, L. Li, K.
- Lu, H. Jiang, Y. Gong, H. Xu, X. Shen, Q. Tian, C. Lv, F. Song, X. Yin, Z. Lu, Post-

- 397 lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan,
- 398 China, Nature Communications 11(1) (2020) 5917.
- 399 [23] S.N. Kain D, Allen V, Evans GA, Hopkins J, Kouyoumdjian FG, McGeer A, Mubareka
- 400 S, Patel SN, Rochon PA, Schwartz B, Juni P, Johnstone J, Routine Asymptomatic SARS-
- 401 CoV-2 Screen Testing of Ontario Long-Term Care Staff After COVID-19 Vaccination.
- 402 https://doi.org/10.47326/ocsat.2021.02.15.1.0>, 2021 (accessed May 14, 2021.).
- 403 [24] G. Caruana, A. Croxatto, E. Kampouri, A. Kritikos, O. Opota, M. Foerster, R. Brouillet,
- 404 L. Senn, R. Lienhard, A. Egli, G. Pantaleo, P.N. Carron, G. Greub, Implementing SARS-
- 405 CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The
- 406 INCREASE Study, Microorganisms 9(4) (2021).
- 407 [25] I. Torres, S. Poujois, E. Albert, J. Colomina, D. Navarro, Evaluation of a rapid antigen
- 408 test (PanbioTM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic
- close contacts of COVID-19 patients, Clin Microbiol Infect 27(4) (2021) 636.e1-636.e4.
- 410 [26] B. Baro, P. Rodo, D. Ouchi, A.E. Bordoy, E.N. Saya Amaro, S.V. Salsench, S. Molinos,
- 411 A. Alemany, M. Ubals, M. Corbacho-Monné, P. Millat-Martinez, M. Marks, B. Clotet, N.
- 412 Prat, O. Estrada, M. Vilar, J. Ara, M. Vall-Mayans, G.B. C, Q. Bassat, I. Blanco, O. Mitjà,
- Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for
- SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison, J Infect 82(6)
- 415 (2021) 269-275.
- 416 [27] E. Surkova, V. Nikolayevskyy, F. Drobniewski, False-positive COVID-19 results:
- 417 hidden problems and costs, The Lancet Respiratory Medicine 8(12) (2020) 1167-1168.
- 418 [28] B. Healy, A. Khan, H. Metezai, I. Blyth, H. Asad, The impact of false positive COVID-
- 419 19 results in an area of low prevalence, Clin Med (Lond) 21(1) (2021) e54-e56.

- 420 [29] P.M. Yip, A.A. Venner, J. Shea, A. Fuezery, Y. Huang, L. Massicotte, N. Tetreault, C.
- 421 Tomalty, J.L.V. Shaw, Point-of-care testing: A position statement from the Canadian Society
- of Clinical Chemists, Clin Biochem 53 (2018) 156-159.

- 423 [30] E.H. Kaplan, H.P. Forman, Logistics of Aggressive Community Screening for
- 424 Coronavirus 2019, JAMA Health Forum 1(5) (2020) e200565-e200565.

Table 1. Weekly APOCT for asymptomatic staff at continuing care sites across Alberta, Canada.

427

428

433

Week	Number	Number of	Positive	Invalid	Number
,, cek	of	tests	APOCTs	APOCTs (%)	confirmed by
	reporting	performed	(%) ^a	711 0013 (70)	rRT-PCR
	sites	Perioriica	(,0)		(%)
Feb 22-28, 2021	11	615	1 (0.16)	4 (0.65)	0
Mar 1-7, 2021	115	2,446	0	4 (0.16)	0
Mar 8-14, 2021	188	4,374	3 (0.07)	16 (0.37)	0
Mar 15-21, 2021	309	8,680	8 (0.09)	29 (0.33)	1 (12.50)
Mar 22-28, 2021	293	7,603	6 (0.08)	4 (0.05)	1 (16.67)
Mar 29-Apr 4, 2021	311	8,029	9 (0.11)	13 (0.16)	5 (55.56)
Apr 5-11, 2021	317	9,599	12 (0.13)	3 (0.03)	8 (66.67)
Apr 12-18, 2021	325	9,312	15 (0.16)	4 (0.04)	6 (40.00)
Apr 19-25, 2021	321	9,541	17 (0.18)	6 (0.06)	10 (58.82)
Apr 26-May 2, 2021	369	11,648	16 (0.14)	4 (0.03)	8 (50.00)
Total	369	71,847	87 (0.12)	87 (0.12)	39 (44.83)

429 Abbreviations: Apr – April; Feb – February; Mar – March; rRT-PCR – real time reverse transcriptase polymerase chain reaction.

431 ^aChange in APOCT positivity across the ten weeks is not significant (Pearson's Chi-square, p=0.35).

Table 2. APOCT and rRT-PCR confirmatory results for asymptomatic continuing care

health care workers in Alberta, Canada.

434

435

438

439

Item	BD Veritor	Panbio	Total (%)
Total APOCTs	17,689	54,158	71,847
Positive APOCTs (%)	47 (0.27)	40 (0.07)	87 (0.12)
Negative APOCTs (%)	n/a	n/a	71,673 (99.76)
Invalid APOCTs (%)	n/a	n/a	87 (0.12)
Positive APOCTs	11 (0.06)	28 (0.05)	39 (0.05)
confirmed by rRT-PCR			
(%)			
Number of false	$36/47 = 76.60\%^{a}$	$12/40 = 30.00\%^{a}$	48/87 = 55.17%
positives (%)			
Positive predictive	$11/47 = 23.40\%^{a}$	$28/40 = 70.00\%^{a}$	39/87 = 44.83%
value (%)			

436 Abbreviations: n/a – not available

^aComparison between BD Veritor and Abbott Panbio: *p*<0.0001.

STROBE CHECKLIST

- Source of STROBE checklist: https://www.strobe-
- 442 statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf

Manuscript title:

440

441

443

444

445

446

447

Multi-centre post-implementation evaluation of SARS-CoV-2 antigen-based point of care

tests used for asymptomatic screening of continuing care healthcare workers

Section	Description	Location in Manuscript
Title and Abstract	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title indicates study type Abstract provides details of outbreak and interventions.
Introduction		
Background and rationale	Explain the scientific background and rationale for the investigation being reported	Introduction – page 4-5
Objectives	State specific objectives, including any prespecified hypotheses	Last paragraph of introduction – page 5.
Methods		
Study design	Present key elements of study design early in the paper	Outlined in Methods – Page 6
Setting	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods – Page 5-7
Participants	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Methods – Page 5 (first paragraph)
Variables	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods – Pages 5-6

Data sources	For each variable of	Mathods Pages 7
Data sources	For each variable of	Methods – Pages 7
	interest, give sources of data	
	and details of methods of	
	assessment (measurement).	
	Describe comparability of	
	assessment methods if there	
	is more than one group	
Bias	Describe any efforts to	Not applicable. There are
	address potential sources of	limitations outlined in the
	bias	discussion.
Study size	Explain how the study size	As this was a retrospective
	was arrived at	review, not applicable.
		However, sample sizes and
		details of data extraction
		provided in Methods page 7
		and Results 7-8.
Quantitative analysis	Explain how quantitative	Methods page 7.
	variables were handled in	1.2000 Page /.
	the analyses. If applicable,	
	describe which groupings	
	were chosen and why	
Statistical methods	Describe all statistical	Methods pages 7.
Statistical illethous	methods	Wethous pages 7.
Results	incurous	
	(a) Report numbers of	Results – Page 8
Participants	-	Results – Page o
	individuals at each stage of	
	study—eg numbers	
	potentially eligible,	
	examined for eligibility,	
	confirmed eligible, included	
	in the study, completing	
	follow-up, and analysed (b)	
	Give reasons for non-	
	participation at each stage	
	(c) Consider use of a flow	
	diagram	
Descriptive data	(a) Give characteristics of	Results – Pages 7-8
	study participants (eg	
	demographic, clinical,	
	social) and information on	
	exposures and potential	
	confounders (b) Indicate	
	number of participants with	
	missing data for each	
	variable of interest (c)	
	Summarise follow-up time	
	(eg, average and total	
	amount)	
Outcome data	Report numbers of outcome	Results pages 7-8, Table 1+2
Cateonie data	events or summary	11000110 pages 7 0, 14010 1 12
	Sychic of Bullillary	

	measures over time	
Main results	(a) Give unadjusted	Results pages 7-8, Table 1+2
Traditi 10001tb	estimates and, if applicable,	11000100 pages 7 0, 14010 1 12
	confounder-adjusted	
	estimates and their precision	
	(eg, 95% confidence	
	interval). Make clear which	
	1	
	confounders were adjusted	
	for and why they were	
	included (b) Report	
	category boundaries when	
	continuous variables were	
	categorized (c) If relevant,	
	consider translating	
	estimates of relative risk	
	into absolute risk for a	
	meaningful time period	N. 1. 1.
Other analyses	Report other analyses	Not applicable.
	done—eg analyses of	
	subgroups and interactions,	
	and sensitivity analyses	
Discussion/Interpretation		
Key results	Summarise key results with	First paragraph of Discussion.
	reference to study	
	objectives	
Limitations	Discuss limitations of the	Limitations section of
	study, taking into account	Discussion (page 11).
	sources of potential bias or	
	imprecision. Discuss both	
	direction and magnitude of	
	any potential bias	
Interpretation	Give a cautious overall	Pages 9-12.
	interpretation of results	
	considering objectives,	
	limitations, multiplicity of	
	analyses, results from	
	similar studies, and other	
	relevant evidence	
Generalisability	Discuss the generalisability	Pages 10-11.
	(external validity) of the	
	study results	
Other		
Funding	Give the source of funding	Outlined in declarations
	and the role of the funders	section.
	for the present study and, if	
	applicable, for the original	
	study on which the present	
	article is based	